Four patients refractory to doxorubicin (DX) and 9 patients refractory to 4'epidoxorubicin (4'EpiDX) were treated with verapamil (VRP) (120 mg every 6 h for 3 days) plus 4'EpiDX (80 mg/m2 i.v. bolus, together with the 6th VRP administration). Three patients had partial remissions lasting 3, 3.5 and 7 months, respectively. Toxicity grading did not exceed usual levels. The study demonstrates that VRP, when added at conventional doses to 4'EpiDX, can induce objective responses in some patients refractory to anthracyclines.
Get full access to this article
View all access options for this article.
References
1.
FormelliF., CleisL., CarsanaR.: Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive tumors.Cancer Chemother. Pharmacol., 21: 329–336, 1988.
2.
FrishmanW., KirstenE., KleinM., PineM., JohnsonS.M., HillL.D., PackerM., KatesR.: Clinical relevance of verapamil plasma levels in stable angina pectoris.Am. J. Cardiol., 50: 1180–1184, 1982.
3.
HubbardS.M., BarkesP., YoungR.C.: Adriamycin therapy in advanced ovarian carcinoma recurrent after chemotherapy.Cancer Treat. Rep., 62: 1375–1378, 1977.
4.
InabaM., KobayashiH., SakuraiY., JohnsonR.K.: Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.Cancer Res., 39: 2200–2203, 1979.
5.
KerrD.J., GrahamJ., CummingsJ., MorrisonJ.G., ThompsonG.G., BrodieM.J., KayeS.B.: The effect of verapamil on the pharmacokinetics of adriamycin.Cancer Chemother. Pharmacol., 18: 239–242, 1986.
6.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment.Cancer, 47: 207–214, 1981.
7.
OzolsR.F., CunnionR.E., KlekerR.W., HamiltonT.C., OstchegaY., ParrilloJ.E., YoungR.C.: Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.J. Clin. Oncol., 5: 641–647, 1987.
8.
PresantC.A., KennedyP., WisemanC., GalaK., WyresM.: Verapamil plus adriamycin. A phase I-II clinical study.Proc. Am. Soc. Clin. Oncol., 3: 32, 1984.
9.
TsuruoT., IidaH., TsukagoshiS., SakuraiY.: Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors.Cancer Res., 42: 4730–4733, 1982.
10.
TsuruoT.: Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics.Cancer Treat. Rep., 67: 889–894, 1983.
11.
TsuruoT., IidaH., NojiriM., TsukagoshiS., SakuraiY.: Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers.Cancer Res., 43: 2905–2910, 1983.
